Paul Joseph DysonPaul Dyson rejoignit l’EPFL en 2002 à la tête du Laboratoire de chimie organométallique et médicinale de l’Institut des sciences et ingénierie chimiques, dont il en assuma ensuite la direction entre 2008 et 2016.
Le prof. Dyson a été récompensé par de nombreux prix dont le Prix Werner de la Société Suisse de Chimie en 2004, le Prix pour les réalisations exceptionnelles en chimie bio organométallique en 2010, la Médaille du Centenaire de la naissance de Luigi Sacconi (2011) de la Société Italienne de Chimie, le Prix de Chimie bio-inorganique de la Royal Society of Chemistry en 2015, le Prix européen pour une chimie durable de la Société Européenne de Chimie en 2018 et le Prix pour la chimie verte de la Royal Society of Chemistry en 2020.
Le prof. Dyson est également mentionné dans la liste établie par Clarivate des chercheurs les plus cités (Clarivate Highly Cited Researcher), avec un H-index >110 (Web of Science et Google Scholar). Paul Dyson a été élu membre de la Royal Société de Chimie en 2010, membre de l’Académie Européenne des Sciences en 2019 et membre à vie de l’Association Américaine pour l’Avancement de la Science en 2020. Au cours des dernières années il s’est vu décerner le titre de Professeurs Hôte par l’Université de Bourgogne, l’Université de Pierre et Marie Curie, l’Université de Vienne, l’Université de Rome Tor Vergara, l'Ecole Nationale Supérieure de chimie de Paris (Chimie ParisTech) et par l’Université de Shangai Jiao Tong.
De 2016 à 2021 il était membre du conseil de la recherche de la division de mathématique, sciences naturelles et de l’ingénieur du Fonds National Suisse. En 2021, il a été nommé doyen de la Faculté des Sciences de Base.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Ursula RöthlisbergerU. Röthlisberger was born in Solothurn (Switzerland). In 1988 she made her diploma in Physical Chemistry in the group of Prof. Ernst Schumacher at the University of Berne (Switzerland). Her Ph.D. thesis was done in collaboration with Dr. Wanda Andreoni at the IBM Zurich Research Laboratory in Rüschlikon. After finishing her Ph.D in 1991 she spent some time as a postdoctoral research assistant at the IBM Research Lab. From 1992-1995 she was a postdoctoral research assistant in the group of Prof. Michael L. Klein at the University of Pennsylvania in Philadelphia (USA). In 1994 she was awarded an advanced researcher fellowship (Profil 2) from the Swiss National Science Foundation. Before starting her Profile 2-fellowship she spent another year as postdoctoral research assistant in the group of Prof. Michele Parrinello at the Max-Planck-Institute for Solid State Physics in Stuttgart, Germany. In 1996 she moved as Profile 2-fellow to the ETH in Zurich, hosted by the group of Prof. Wilfred F. van Gunsteren. In 1997 she became Assistant Professor of Computer-Aided Inorganic Chemistry at the ETH Zurich.
Vassily HatzimanikatisDr. Vassily Hatzimanikatis is currently Associate Professor of Chemical Engineering and Bioengineering at Ecole Polytechnique Federale de Lausanne (EPFL), in Lausanne, Switzerland. Vassily received a PhD and an MS in Chemical Engineering from the California Institute of Technology, and his Diploma in Chemical Engineering from the University of Patras, in Greece. After the completion of his doctoral studies, he held a research group leader position at the Swiss Federal Institute of Technology in Zurich (ETHZ), Switzerland. Prior to joining EPFL, Vassily worked for three years in DuPont, Cargill, and Cargill Dow, and he has been assistant professor at Northwestern University, at Illinois, USA.
Vassilys research interests are in the areas of computational systems biology, biotechnology, and complexity. He is associate editor of the journals Biotechnology & Bioengineering, Metabolic Engineering and Integrative Biology, and he serves on the editorial advisory board of the journals Bioprocess and Biosystems Engineering, Journal of Chemical Technology and Biotechnology, and Industrial Biotechnology. He has written over 70 technical publications and he is co-inventor in three patents and patent applications.
Vassily is a fellow of the American Institute for Medical and Biological Engineering (2010), he was a DuPont Young Professor (2001-2004), and he has also received the Jay Bailey Young Investigator Award in Metabolic Engineering (2000), and the ACS Elmar Gaden Award (2011).
Lukas KühnLukas Kühn graduated in biochemistry at the Swiss Federal Institute of Technology in Zürich. He received his PhD in 1979 for a thesis with Jean-Pierre Kraehenbuhl at the University of Lausanne. After postdoctoral work in Lausanne and with Frank Ruddle at Yale University, USA, he became group leader at ISREC in 1984, was promoted senior scientist in 1988 and EPFL Adjunct Professor (professeur titulaire) in June 2008.
Gerardo TurcattiSenior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
